When the Food and Drug Administration said last month that Dr. Richard Pazdur, a long-tenured, widely-respected FDA leader, would lead the agency’s drug review division, it seemed a sign that things ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback